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Abstract
Background: Arum palaestinum is a plant commonly found in the Middle East that is ingested as an herbal remedy
to fight cancer. However, no studies have examined the direct effect of the plant/plant extract on tumor growth in
an animal model.
Methods: Verified prostate cancer cells were plated as 3D spheroids to determine the effect of extract from boiled
Arum Palaestinum Boiss roots. In addition, male NU/NU mice (8 weeks old) with xenograft tumors derived from the
prostate cancer cell line were treated daily with 1000 mg/kg body weight gavage of the suspension GZ17. The
tumor growth was measured repeatedly with calipers and the excised tumors were weighed at the termination of
the 3 week study. Control mice (10 mice in each group) received vehicle in the same manner and volume.
Results: The number of live prostate cancer cells declined in a dose/dependent manner with a 24 h exposure to
the extract at doses of 0.015 to 6.25 mg/mL. A fortified version of the extract (referred to as GZ17) that contained
higher levels of isovanillin, linolenic acid and β-sitosterol had a stronger effect on the cell death rate, shifting the
percentage of dead cells from 30 % to 55 % at the highest dose while the vehicle control had no effect on cell
numbers. When GZ17 was applied to non-cancer tissue, in this case, human islets, there was no cell death at doses
that were toxic to treated cancer cells. Preliminary toxicity studies were conducted on rats using an up-down
design, with no signs of toxic effect at the highest dose. NU/NU mice with xenograft prostate tumors treated with
GZ17 had a dramatic inhibition of tumor progression, while tumors in the control group grew steadily through the
3 weeks. The rate of tumor volume increase was 73 mm3/day for the vehicle group and 24 mm3/day for the GZ17
treated mice. While there was a trend towards lower excised tumor weight at study termination in the GZ17
treatment group, there was no statistical difference.
Conclusions: Fortified Arum palaestinum Boiss caused a reduction in live cells within prostate cancer spheroids and
blocked tumor growth in xenografted prostate tumors in mice without signs of toxicity.
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Background
The use of herbal remedies is widespread in both develop-
ing and developed countries [1]. This type of treatment is
vitally important to populations without other healthcare
options. In 2002, the World Health Organization esti-
mated that 80 % of the world’s population in developing
countries depended on plants and traditional medicine
practitioners to meet their primary health care needs [2].
In addition, the use of herbals and the subsequent analysis
of active ingredients has been important in the formation
of many modern drugs.
Wild edible plants have always been an important
source of therapeutics in traditional folk medicine. One
of the most common plants ingested in the Palestinian
region is the Arum palaestinum Boiss [3], also known
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as the Black Calla Lily. Often it is boiled and then the
leaves are fried in olive oil and eaten because it is be-
lieved to protect from colon cancer. It is also commonly
ingested as a tea. In fact, Arum palaestinum Boiss is
one of the most commonly utilized plants for cancer pa-
tients in the region [3]. Nearly 40 % of the cancer pa-
tients ingesting the plant revealed that they anticipated
a cure due to the plant. Yet, little is known about its ac-
tive ingredients or its efficacy as an anticancer agent. In
fact, there is a paucity of published articles devoted to
the potential medicinal effects of this plant.
Arum palaestinum Boiss is a member of the Araceae
family of plants, many of which contain polyphenols, al-
kaloids, flavone C-glycosides, flavonols, flavones,
proantrhocyanidins and polyhydroxy alkalokds [4–7].
The plant is known to contain antioxidant activity [4, 8].
Some active compounds have been isolated directly from
Arum palaestinum Boiss including two flavone C-
glucosides (isoorientin and vitexin) [9]. Previously, we
undertook studies to identify the active ingredients of
Arum palaestinum Boiss and identified isovanillin, lino-
lenic acid and β-sitosterol as major contributors. The
purpose of this study was to determine whether native
Arum palaestinium Boiss and its fortified version had
anti-cancer activity against aggressive androgen-
independent prostate cancer models in vitro and in vivo.
Methods
Plant extract preparation
Arum palaestinum Boiss roots and leaves were collected
from wild samples or were cultivated on site. Samples
were submitted to the Missouri Botanical Garden, St.
Louis, MO for verification (voucher number, Croat
95,466(MO). Approximately 14 g of Arum palaestinum
Boiss leaves and roots were placed in 1 L of water and
brought to a boil for 15 min, followed by reduced heat
for another 15 min. The mixture was filtered to remove
large particles, resulting in the plant extract that was
used in testing.
When working with plant extracts, the exact amount of
each chemical component is difficult to control from plant
to plant. Chemical components of the extract have been
described elsewhere [10]. Three of the chemical compo-
nents were fortified to known quantities, resulting in a
compound termed “GZ17”. Isovanillin, linolenic acid and
β-sitosterol (25 g each) (Sigma-Aldrich, St. Louis, MO)
were diluted in the Arum palaestinum Boiss elixir com-
posed of 15 g of Arum palaestinum Boiss extract in 3.79 L
of H2O for a final concentration of 43.3 μM isovanillin,
23.8 μM linolenic acid, and 15.9 μM β-sitosterol. GZ17
was diluted in purified water and sonicated to achieve a
50 mg/mL stock solution and diluted in water to specified
concentrations. The suspension was stored at 4 °C,
shielded from light, and vortexed vigorously prior to use.
To concentrate the elixir for in vitro studies, a powder
version was obtained by drying using rotoevaporation,
followed by exposure to nitrogen to drive all remaining
liquid out of the product, followed by manual
pulverization.
Cell culture and dose response
Vascular smooth muscle cells (PCS-100-021), dermal
fibroblasts (HGF-1) and prostate cancer cells (22Rv1)
were obtained from ATCC and verified within 2 pas-
sages of the use of the cells. Prostate cancer cells
(22Rv1) are a recognized cell model of androgen-
independent prostate cancer [11]. The cells were
grown in RPMI supplemented with 10 % FBS + 1 %
anti-anti. Cells were plated in a 3D cell culture sys-
tem (Micromold, Likarda, LLC) to form spheroids of
an average of 40 microns in diameter in 48 h.
Methods for fabrication of the micromold and loading
cultured cells into the micromold plate have been
published previously [12, 13]. On day two, the spher-
oids are transferred to 96 well plates with an average
of 50 spheroids/well.
Prostate cancer spheroids were exposed to increasing
doses of the extract of Arum palaestinium Boiss, GZ17
(dose range from 0 – 6.25 mg/mL), or equivalent vehicle
for 24 h prior to assays. Each trial was run with at least
four replicates at each dose. At the completion of the ex-
posure time, PrestoBlue (Life Technologies, Inc) was added
to each well and fluorescence read (ex. 485/em. 560) on a
microplate reader (Enspire Multimode, PerkinElmer) 4 to
6 h later. Results were averaged following background sub-
traction and normalized to untreated cells.
Toxicity studies were conducted on freshly isolated
human islets, cultured vascular smooth muscle cells, and
cultured fibroblasts. Fibroblasts were cultured in DMEM
with 10 % FBS and 1 % strep/pen to 80 % confluency
prior to testing. Vascular smooth muscle cells were
grown in Vascular Cell Basal Medium supplemented
with Vascular Smooth Muscle Growth Kit components
(ATCC) to a confluency of 80–90 %.
Human islets were obtained from the Integrated Islet
Distribution Program (City of Hope Hospital, Duarte,
CA). Human islets were manually dispensed into a 96
well plate and exposed to increasing doses of GZ17 (4
replicates each) for 24 h. Followed by the addition of
PrestoBlue (Life Technologies, Inc) to each well, fluores-
cence was read on a microplate reader (Enspire Multi-
mode, PerkinElmer) 4 to 6 h later. Results were averaged
following background subtraction.
Mechanism of action
Cultured prostate cancer cells (22RVI) were seeded into
96-well plates at a density of 5,000 cells/well and allowed
to grow for 48 h until 80–90 % confluent. The cells were
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exposed to 8 to 10 doses of GZ17 diluted in RPMI with
10 % FBS. Four replicates at each concentration were
tested along with replicates of media only, and cells plus
media only, 100 microliters total volume per well. Cells
were exposed to GZ17 concentrations for 24 h at 37 °C
and 5 % CO2. Caspase 6 Glo Reagent (Promega) was
allowed to equilibrate to room temperature, and subse-
quently added in a 1:1 ratio to each well and left to incu-
bate for 45 to 60 min. Luminescence was read with a
plate reader (Perkin Elmer, Enspire). Changes in signal
for assays were background subtracted and normalized
to the 0 drug baseline.
In Vivo toxicity
A single dose of 5000 mg/kg was administered by oral gav-
age to 10 week old female Sprague–Dawley rats, weighing
between 170–200 gm (Ace Animals, Boyertown, PA). The
animals were housed in an Association for the Assessment
and Accreditation of Laboratory Animal Care (AAALAC)-
accredited facility and the protocol was approved by the In-
stitutional Animal Care and Use Committee (IACUC) of
Eurofins Scientific following GLP standards. Over the sub-
sequent 14 days, animals were weighed and activity was
observed. Specifically, daily evaluations included skin, fur,
eyes, mucous membranes, respiratory rate, and central ner-
vous system behavior. Particular attention was directed for
signs of tremors, convulsions, salivation, diarrhea and
coma. At completion of the 14 days, the animals were eu-
thanized, and the tissues and organs of the thoracic and ab-
dominal cavities were examined.
In Vivo efficacy
Male NU/NU mice (8 weeks old) were obtained from
Charles River Laboratories, Inc. The animals were
allowed to acclimate for a week and were housed in an
Association for the Assessment and Accreditation of La-
boratory Animal Care (AAALAC)-accredited facility and
the protocol was approved by the Institutional Animal
Care and Use Committee (IACUC) of Xenometrics,
LLC. The mice and rats were held in cages with twelve
hour light /dark periods, and were treated ethically
throughout the study. Animal distress was monitored
daily and no animals showed signs of distress through-
out the study. Mice had access to food and water ad libi-
tum, except for the 3 h period in the morning prior to
treatment. Cancer cells from a prostate tumor cell line
(PC3-MM2) were brought up in phosphate buffered sa-
line (PBS). The immunocompromised mouse model using
the androgen independent PC3-MM2 cells has been
shown to be one of the most robust models for prostate
cancer [14]. Approximately 106 cells/100-200 μL of PBS
were injected subcutaneously into the flank of each
mouse. Tumors were allowed to develop to a measurable
size prior to the initiation of the treatment with GZ17.
Seven days following the injection of the cancer cells, tu-
mors were visible and baseline tumor measurements were
performed. The tumor size was measured with calipers
twice weekly.
Animal treatment protocol
Twenty mice were divided into treatment and vehicle
groups (10 each) according to tumor size so that both
groups had animals with matched tumor burdens. After
nine days of monitoring the animals, GZ17 or the ve-
hicle (purified water) was administered via an oral gav-
age of 1000 mg/kg in the morning at a volume of
20 mL/kg for 21 days. Food was removed from the cage
3 h prior to each dosing and was returned 1 h after the
dosing. Animals were monitored twice daily for signs of
acute or chronic pain due to the tumor burden and were
euthanized by CO2 asphyxiation along with cervical dis-
location. Tumors and organs were dissected, cleaned of
fat and connective tissue and weighed.
Statistical analysis
Statistical analysis was completed comparing the
vehicle-treated and GZ17-treated mice using a Student’s
t-test, or Mann Whitney Rank Sums when normality
was not achieved. Repeated measures analysis of vari-
ance (ANOVA) was used to compare tumor sizes within
animals; p < 0.05.
Results
In Vitro prostate cancer spheroid effect
Prostate cancer spheroids were exposed to increasing
doses of Arum palaestinum Boiss extract or to the forti-
fied version of the plant extract called GZ17. Both
showed a dose-dependent increase in cell death at con-
centrations ranging from 0.015 to 6.25 mg/mL, but the
GZ17 was slightly more potent at inducing cell death in
the spheroids (Fig. 1a). IC50 values could not be calcu-
lated, as the maximal effect could not be reached with
the highest concentration of the pure plant extract due
to its precipitation at higher concentrations. For this rea-
son, the extract was dried to obtain a solid form for re-
constitution in water. The effect on prostate cells was
more evident using the reconstituted version of GZ17
(Fig. 1b). It was compared to the vehicle control, which
induced no cell death at the same concentrations. In
contrast, the GZ17-treated plates lost 96 % of the cells
at the highest GZ17 dose (6.25 mg/mL).
The fortifying components added to Arum palaestinum
Boiss to create GZ17 were tested alone for any effect on
prostate cancer cells. Figure 1c illustrates the lack of re-
sponse when the 3 fortifying components (isovanillin, lino-
lenic acid and β-sitosterol) were applied to the cancer cells
alone. In contrast, when the 3 were combined with the
plant to form GZ17, the cell death rate was greatly
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enhanced to the point that nearly all cells were dead at the
highest tested dose.
To determine the method of cell death, activation of
caspase proteins were surveyed. Figure 2 shows dose re-
sponse (log dose) of caspase 6 in prostate cancer when
exposed to GZ17. While cell death was measured at
GZ17 doses of 0.2 mg/mL GZ17 (Fig. 1b), caspase acti-
vation was measured far earlier below 0.1 mg/mL.
To determine whether the cell death effect of GZ17
was specific to cancer cells, non-cancerous human islets
were exposed to the same doses of GZ17 for 24 h. GZ17
caused no cell-death on the human islets with cell num-
bers greatest at the highest doses (Fig. 3a). In contrast,
GZ17 caused a dose-specific cell death in the prostate
cancer spheroids with a half maximal inhibitory concen-
tration (IC50) of approximately 3 mg/mL and only 8.5 %
of the total number of cells alive when exposed to
6.25 mg/mL GZ17. Using the same methods, IC50 levels
were determined for GZ17 on non-cancerous vascular
smooth muscle cells and fibroblasts. Figure 3b summa-
rizes the higher dose required to achieve the IC50 level
in the fibroblasts and smooth muscle cells compared to
the prostate cancer cells.
In Vivo toxicity
An up and down toxicity design was used to gather pre-
liminary data on in vivo toxicity of the ingested GZ17. A
single female rat was given a one-time maximal dose of
GZ17 (5000 mg/kg). The rat was observed for signs of
gross toxicity, mortality and behavioral changes daily for
the following 2 weeks. No signs of pain related behavior,
respiratory or cardiovascular distress, tremors, convul-
sions, salivation, diarrhea, or coma were noted. Skin and
fur, eye and mouth mucosa, and central nervous system
Fig. 1 Prostate cancer spheroids respond to Arum paleastinum Boiss and the fortified GZ17. a Prostate cancer cells grown in 3D spheroids
responded to Arum palaestinum Boiss and the fortified version, GZ17, in a dose dependent manner. GZ17 was more potent at inducing cell
death compared to the plant extract with statistically lower cell numbers at 3.13 and 6.25 mg/ml. b Compared to the vehicle, which had no cell
death effect, GZ17 was statistically more potent at inducing cell death. c The 3 fortifying components that when added to Arum palaestinum,
create GZ17, were tested alone on prostate cells. The additives (open circles) had little effect on cell viability. *indicates p < 0.005; **indicates p < 0.001
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function were normal. Upon necropsy at the completion
of the study, all abdominal and thoracic tissues were
normal. With no lethality or toxicity signs or symptoms
noted, two additional rats were dosed at the same
5000 mg/kg level with similar outcomes. The subse-
quent animal subjects also showed no gross signs of
toxicity and no organ abnormality at the time of nec-
ropsy. Table 1 provides the weight gain for each animal
following the maximal dose, demonstrating normal
weight gain.
In Vivo prostate cancer effect
Having determined that GZ17 contained anti-cancer
properties on prostate cancer cells in vitro with no signs
of toxicity in rats, the compound was used for
complimentary in vivo studies, employing a mouse
model of prostate cancer. Prostate cells were injected
into all mice to form tumor-like masses prior to treat-
ment with GZ17. The animals used in this study ap-
peared healthy throughout the treatment. Redness was
noted over the tumor region 7 days after the injection
Fig. 2 GZ17 induces a dramatic increase in caspase 6 levels. Prostate cancer spheroids were exposed to increasing doses of GZ17 and caspase 6
levels measured. Caspase 6 increased 3 times, beginning at low doses. * indicates significant increase over baseline, p < 0.005
Fig. 3 GZ17 is less toxic on non-cancer human islets. a The cell death inducing activity of GZ17 was compared in human prostate cancer
spheroids and human non-cancerous islets. GZ17 failed to induce cell death in the human islets, but consistently caused a dramatic loss
of cancer cells. *indicates p < 0.01 and ** indicates p < 0.001 when comparing the islet and prostate cancer results at each dose. b The
IC50 for vascular smooth muscle cells and human fibroblast cells were compared to the value for prostate cancer cells
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of tumor cells but was resolved without obvious stress
to the animal.
Control mice received the vehicle, while the experi-
mental group received the extract version of GZ17 via
oral gavage once/day for 3 weeks. Mice were weighed
twice weekly. There was no difference in body weight
between the two groups throughout the study (Fig. 4).
There was a 6.1 % increase in average weight of the
vehicle-treated mice, and a 3.5 % increase in average
weight of the GZ17-treated animals. The difference was
not statistically significant and began prior to the initi-
ation of the GZ17 treatment.
Tumor sizes were measured twice per week. Prostate
tumors grew steadily throughout the 3-week treatment
period in the vehicle-treated mice. There was a 122 %
increase in tumor size by the end of the study in the
vehicle-treated animals (Fig. 5). GZ17 slowed tumor
growth when compared to the vehicle group with only a
9.6 % increase in tumor size. By day 6 and for all subse-
quent measurements there was a statistically significant
increase in the tumor volume of the vehicle-treated
mice. There was no statistically significant increase in
tumor size until day 16 in the GZ17-treated group. The
rate of tumor volume increase was 73 mm3/day for the
vehicle group and 24 mm3/day for the GZ17 treated
mice. Tumor growth delay was measured when control
tumors reached a volume of 500 mm3, which occurred
on day 7.1 in the control animals and day 16.3 in the
GZ17-treated mice. On the day of euthanasia, the aver-
age tumor volume was more than double in the controls
compared to the treated mice. Furthermore, treated
mice showed no changes in behavior, activity levels,
grooming or other indications of altered general health.
At completion of the study, the tumors were excised and
weighed. The tumors in the vehicle-treated mice
weighed 58 % more than the treated group, but there
was no statistical difference between the two groups.
In order to assess whether GZ17 caused unintended
side effects, organs from all animals in the 3-week treat-
ment study were removed, inspected and weighed. In
agreement with the earlier rat studies, there were no ad-
verse signs of drug effect such as altered gross morph-
ology of the organs analyzed, including indications of
metastasis, in the brain, heart, kidneys, liver, lungs, or
spleen. There were no differences in the weights of the
six organ tissues between the vehicle and GZ17 treated
groups, and when organ weights were normalized to the
body weight of each animal (Table 2).











1 170 193 239 71
2 200 219 248 81
3 176 194 240 73
Fig. 4 Animal weight. Mice were weighed prior to treatment with
GZ17 or the vehicle. Treatment began on day 0. There was no
statistical difference in the body weights of either group of mice
throughout the 3-week study
Table 2 Mouse organ weight
Tissue Vehicle GZ17 P
Brain 0.40 ± 0.03 0.40 ± 0.04 0.94
Heart 0.18 ± 0.01 0.19 ± 0.01 0.35
Kidney 0.44 ± 0.03 0.46 ± 0.02 0.59
Liver 1.41 ± 0.08 1.40 ± 0.10 0.86
Lung 0.22 ± 0.02 0.28 ± 0.03 0.16
Spleen 0.09 ± 0.01 0.09 ± 0.01 0.57
Fig. 5 Tumor volume. Tumor volume was measured in 3 dimensions
with calipers. The size of the tumors and the rate of tumor growth
were both statistically greater in the vehicle-treated mice, compared to
the GZ17. **indicates p< 0.001; *indicates p < 0.001 for comparisons
between effects of days of treatment and baseline tumor volume
within groups (repeated ANOVA)
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Discussion
Complementary medicine is commonly used among
cancer patients. In fact, 52 % of cancer patients taking
chemotherapy admitted to the use of herbal teas, yet
nearly half of these individuals had not shared this infor-
mation with their oncologists [15]. Classical research
focusing on a single active compound disregards the
historical knowledge of the traditional remedy and the
source of the plant. One of the main challenges in work-
ing with herbs and understanding their mechanism of
action is the fact that plant-based compounds contain a
number of potentially active chemicals and the quantity
and quality of those compounds may differ based on the
plant’s environment during the growing season [16]. For
this reason, the work here identified three new compo-
nents of Arum palaestinium Boiss. The fortification of
the plant extract with these compounds ensured a
threshold amount for each component regardless of
differences inherent between plants. Alone, these three
components failed to induce dramatic cell death, but
when added to the plant extract a greater level of cell
death was noted at lower doses.
The tumor-limiting effect of GZ17 in this study, in
both cell culture and in mice, builds on previous publi-
cations showing in vitro inhibition of tumor growth by
native Arum palaestinum Boiss. In previous studies, the
ethyl acetate-identified fraction of the plant was shown
to suppress in vitro cell proliferation of breast cancer
(MCF07 cells) [4] and lymphoblastic leukemia cells
(1301) in a dose-dependent manner [7]. However, the
same fraction failed to suppress growth of a liver cancer
cell line (Hep G2) [7]. This is the first published paper
showing in vitro cancer cell suppression for prostate
cancer with activation of caspase 6, as well as in vivo
tumor suppression of prostate cancer in mice. Caspase 6
has been termed an effector caspase, along with caspases
3 and 7, which are activated intrinsically or extrinsically
by one of the initiator caspases, 2, 9, 8, or 10 [17]. We
confirm here that caspase 6 levels increase at doses
lower than cell death was measured. Caspase 6 has been
long identified as being associated with prostate cancer.
In fact, out of 107 prostate human adenocarcinomas
analyzed, 61 % of prostate tumors had high caspase 6
activity, suggesting apoptotic deregulation may occur in
early stages of prostate cancer [18]. Further, resistance
to chemotherapies has been associated with changes in
the caspase genes, with caspase 6 in particular showing
association to drug resistance [19]. Thus, caspase 6 has
been established as an important marker for prostate
cancer [18].
The in vivo studies illustrated the efficacy by inhi-
biting the growth rate of the xenotransplanted pros-
tate tumors in mice. Perhaps one of the most
important findings of this paper is that an extremely
high dose of the extract (1000 mg/kg body weight)
administered for 3 weeks did not cause obvious side
effects in the mice or visible changes in any organs.
These results are consistent with the in vitro toxicity
study on non-cancerous human islets and the rat
toxicity study at 5000 mg/kg, and provide surprising
results as to how well the plant extract was tolerated
in both rats and mice.
Conclusions
While there was previously anecdotal evidence that
Arum palaestinum Boiss benefits cancer patients [3],
this is the first published study measuring the tumor
suppressing effect of the fortified plant on an animal
model of cancer. These results clearly demonstrate an
effect of fortified Arum palaestinum Boiss on suppress-
ing prostate cancer cells and prostate tumors in mice.
While the results are encouraging, additional studies
should be done to elucidate the underlying mecha-
nism(s) of action and the potential activity on other
types of cancers.
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